key: cord-1042160-puhb5vvr
authors: Dirim, Ahmet Burak; Safak, Seda; Andac, Berk; Garayeva, Nurana; Demir, Erol; Artan, Ayse Serra; Ozluk, Yasemin; Kilicaslan, Isin; Oto, Ozgur Akin; Ozturk, Savas; Yazici, Halil
title: Minimal change disease following vaccination with CoronaVac
date: 2021-07-06
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab123
sha: 967749d82a9517894807fccfc997d1017a6477a3
doc_id: 1042160
cord_uid: puhb5vvr

nan

As serum creatinine level increased to 2.1 mg/dL, the dosage of furosemide was reduced. After 12 days of corticosteroid treatment, UPCR declined to 0.33 g/g, and serum albumin increased to 3.01 g/dL ( Figure 1) . A 12-week steroid tapering regimen was prescribed, and diuretic treatment was discontinued due to reaching the basal weight.

The pathogenesis of MCD is still not well known. However, dysregulation in T-cell-mediated immunity is thought to be the main culprit. In particular, increased type-2 T helper cell activity causes cytokine release and the formation of a permeability factor, which has been hypothesized in the pathogenesis of MCD. Medications such as D-penicillamine, infections, autoimmune diseases and malignancies could be causative factors [4] . Also, allergens, bee stings and vaccines could trigger MCD [5] .

MCD is not uncommon following the administration of vaccines. Development of MCD has been reported after influenza, hepatitis B, pneumococcal, measles and tetanus-diphtheria-poliomyelitis vaccines [6] . A recent publication reported a patient with MCD following the Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine [7] . Symptoms started 4 days after the vaccination in that case, and proteinuria was resolved after 2 weeks of 80 mg/day prednisone, similar to our patient.

To the best of our knowledge, CoronaVac-associated newonset nephrotic syndrome has not been reported before. On the other hand, COVID-19 vaccines may cause a flare in patients with glomerulonephritis. Consequently, individuals should be monitored carefully for side effects after vaccinations. Level of serum albumin (g/dL), serum creatinine (mg/dL) or UPCR (g/g) FIGURE 1: The course of the serum albumin (g/dL), UPCR (g/g) and serum creatinine (mg/dL) during follow-up. 

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Looking beyond COVID-19 vaccine phase 3 trials

Minimal change disease

Idiopathic nephrotic syndrome and atopy: Is there a common link?

Vaccine-associated kidney diseases: A narrative review of the literature

Minimal change disease following the Pfizer-BioNTech COVID-19 vaccine

anti-dsDNA, anti-double-stranded DNA antibody

HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus

HDL, high-density lipoprotein

HIV, human immunodeficiency virus; LDL, low-density lipoprotein

TG, triglyceride; TSH, thyroid-stimulating hormone

The authors declare no conflicts of interest.